Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 1.00 |
| ▸ | PPARA | Q07869 | 5/20 | 1.00 |
| ▸ | PPARD | Q03181 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw7845 SCHEMBL29398540 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| Gw7845 SCHEMBL614392 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL7920827 | 0.94 | PPARG (0.89) | PPARGPPARAPPARD | |
| SCHEMBL29524132 | 0.92 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL17471268 | 0.92 | PPARG (1.00) | PPARGPPARAPPARD | |
| Farglitazar SCHEMBL14281408 | 0.91 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL2812865 | 0.91 | PPARG (1.00) | PPARGPPARAPPARD | |
| Farglitazar SCHEMBL2208414 | 0.91 | PPARG (1.00) | PPARGPPARAPPARD | |
| Farglitazar SCHEMBL501024 | 0.91 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL7926328 | 0.89 | PPARG (0.87) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981522-A1 | PPAR AGONISTS | Salk Institute for Biological Studies (US) | 2016-02-10 | — | — | EP | claimed |
| US-20160023991-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-01-28 | — | — | US | claimed |
| WO-2014165827-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2014-10-09 | — | — | WO | claimed |
| US-20070249561-A1 | Pharmacological method for treatment of neuropathic pain | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2007-10-25 | — | — | US | claimed |
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | claimed |
| US-6291496-B1 | E.G., WITH OVEREXPRESSSION OF HER-2/NEU OR OVEREXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR, ARE TREATED WITH STRONGLY BINDING PPAR GAMMA LIGANDS. | CORNELL RESEARCH FOUNDATION, INC. | 2001-09-18 | — | — | US | claimed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | claimed |
| US-11420934-B2 | PPAR agonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-08-23 | — | — | US | disclosed |
| US-20200190019-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-18 | — | — | US | disclosed |
| US-10550071-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180170857-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-06-21 | — | — | US | disclosed |
| US-9938234-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160023991-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-01-28 | — | — | US | disclosed |
| US-7078397-B2 | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-18 | — | — | US | disclosed |
| WO-2005041923-A1 | COMPOSITIONS AND DOSAGE FORMS FOR ENHANCED ABSORPTION OF METFORMIN | ALZA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1368011-A1 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES | SmithKline Beecham Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030166578-A1 | COMBINATIONS OD DIPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT OF DIABETES MELLITUS | SMITHKLINE BEECHAM CORPORATION | 2003-09-04 | — | — | US | disclosed |
| WO-2002067912-A2 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES OR CONDITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
| US-6291496-B1 | E.G., WITH OVEREXPRESSSION OF HER-2/NEU OR OVEREXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR, ARE TREATED WITH STRONGLY BINDING PPAR GAMMA LIGANDS. | CORNELL RESEARCH FOUNDATION, INC. | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420934-B2 | PPAR agonists | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
| US-20070249561-A1 | Pharmacological method for treatment of neuropathic pain | PPARG, PPARA, CNR2 | PPARG 1/4885PPARA 2/4885PPARD 8/4885 |
| US-20180170857-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20160023991-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
| US-20200190019-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
| US-10550071-B2 | PPAR agonists | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.